Quantum jump in biopharmaceutical industry: a case of Korea’s catching up with Europe and US

References

• Arora, A., A. Fosfuri, and A. Gambardella. 2001. “Markets for Technology and Their Implications for Corporate Strategy.” Industrial and Corporate Change 10 (2): 419–451. doi:10.1093/icc/10.2.419.
   Google Scholar
• Asheim, B., and L. Coenen. 2005. “Knowledge Bases and Regional Innovation Systems: Comparing Nordic Clusters.” Research Policy 34 (8): 1173–1190. doi:10.1016/j.respol.2005.03.013.
   Web of Science ®Google Scholar
• Baum, J., T. Calabrese, and B. Silverman. 2000. “Don't Go It Alone: Alliance Network Composition and Startups’ Performance in Canadian Biotechnology.” Strategic Management Journal 21 (3): 267–294. doi:10.1002/(SICI)1097-0266(200003)21:3<267::AID-SMJ89>3.0.CO;2-8.
   Web of Science ®Google Scholar
• Casper, S. 2007. “How Do Technology Clusters Emerge and Become Sustainable?: Social Network Formation and Inter-Firm Mobility Within the San Diego Biotechnology Cluster.” Research Policy 36 (4): 438–455. doi:10.1016/j.respol.2007.02.018.
   Web of Science ®Google Scholar
• Casper, S. 2009. “Institutional Frameworks and Public Policy Towards Biotechnology: Can Asia Learn from Europe?” Asian Business & Management 8 (4): 363–394. doi:10.1057/abm.2009.13.
   Web of Science ®Google Scholar
• Casper, S., and A. Karamanos. 2003. “Commercializing Science in Europe: The Cambridge Biotechnology Cluster.” European Planning Studies 11 (7): 805–822. doi:10.1080/0965431032000121355.
   Web of Science ®Google Scholar
• Casper, S., and H. Kettler. 2001. “National Institutional Frameworks and the Hybridization of Entrepreneurial Business Models: The German and UK Biotechnology Sectors.” Industry and Innovation 8 (1): 5–30. doi:10.1080/13662710120034383.
   Google Scholar
• CBRE Research. 2022. Accessed 14 September 2022. http://cbre.vo.llnwd.net/grgservices/secure/Life-Sciences-Talent-2022.pdf?e = 1663145979&h = ff7be3980e523e5527a7ea41e096d720.
   Google Scholar
• Chesbrough, H. 2003. Open Innovation: The New Imperative for Creating and Profiting from Technology. Brighton, MA: Harvard Business Press.
   Google Scholar
• Churet, C., and R. Eccles. 2014. “Integrated Reporting, Quality of Management, and Financial Performance.” Journal of Applied Corporate Finance 26 (1): 56–64. doi:10.1111/jacf.12054.
   Google Scholar
• Cooke, P. 2002a. “Regional Innovation Systems: General Findings and Some New Evidence from Biotechnology Clusters.” The Journal of Technology Transfer 27 (1): 133–145. doi:10.1023/A:1013160923450.
   Google Scholar
• Cooke, P. 2002b. “Biotechnology Clusters as Regional, Sectoral Innovation Systems.” International Regional Science Review 25 (1): 8–37. doi:10.1177/016001760202500102.
   Web of Science ®Google Scholar
• Cooke, P. 2003. “Biotechnology Clusters. Big Pharma'and the Knowledge-Driven Economy.” International Journal of Technology Management 25 (1-2): 65–80. doi:10.1504/IJTM.2003.003090.
   Web of Science ®Google Scholar
• Cooke, P., M. Uranga, and G. Etxebarria. 1997. “Regional Innovation Systems: Institutional and Organisational Dimensions.” Research Policy 26 (4-5): 475–491. doi:10.1016/S0048-7333(97)00025-5.
   Web of Science ®Google Scholar
• Danzon, P., A. Epstein, and S. Nicholson. 2007. “Mergers and Acquisitions in the Pharmaceutical and Biotech Industries.” Managerial and Decision Economics 28 (4-5): 307–328. doi:10.1002/mde.1343.
   Google Scholar
• Dodgson, M., D. Gann, and A. Salter. 2006. “The Role of Technology in the Shift Towards Open Innovation: The Case of Procter & Gamble.” Research and development Management 36 (3): 333–346. doi:10.1111/j.1467-9310.2006.00429.x.
   Google Scholar
• Dodgson, M., J. Mathews, T. Kastelle, and M. Hu. 2008. “The Evolving Nature of Taiwan's National Innovation System: The Case of Biotechnology Innovation Networks.” Research Policy 37 (3): 430–445. doi:10.1016/j.respol.2007.12.005.
   Web of Science ®Google Scholar
• Doloreux, D., and S. Parto. 2005. “Regional Innovation Systems: Current Discourse and Unresolved Issues.” Technology in Society 27 (2): 133–153. doi:10.1016/j.techsoc.2005.01.002.
   Google Scholar
• Dor, A., J. Guan, A. Kelleher, A. Lauretig, R. Preclaw, and X. Zeng. 2022. “ESG and Alternative Data: Capturing Corporates’ Sustainability-Related Activities with Job Postings.” The Journal of Financial Data Science 4 (1): 130–144. doi:10.3905/jfds.2021.1.082.
   Google Scholar
• Ellram, L. 1996. “The use of the Case Study Method in Logistics Research.” Journal of Business Logistics 17: 93.
   Google Scholar
• Fairfield, P., S. Ramnath, and T. L. Yohn. 2009. “Do Industry-Level Analyses Improve Forecasts of Financial Performance?” Journal of Accounting Research 47: 147–178. doi:10.1111/j.1475-679X.2008.00313.x.
   Web of Science ®Google Scholar
• Farjami, A., S. Montazersaheb, S. Soofiyani, P. Akbarzadehlaleh, and S. Salatin. 2022. “Biopharmaceuticals for Prevention of COVID-19: A Scoping Review.” Asian Pacific Journal of Tropical Medicine 15 (6): 245. doi:10.4103/1995-7645.348158.
   Web of Science ®Google Scholar
• George, G., S. Zahra, K. Wheatley, and R. Khan. 2001. “The Effects of Alliance Portfolio Characteristics and Absorptive Capacity on Performance: A Study of Biotechnology Firms.” Journal of High Technology Management Research 12 (2): 205–226. doi:10.1016/S1047-8310(01)00037-2.
   Google Scholar
• Gunasekara, C. 2006. “Reframing the Role of Universities in the Development of Regional Innovation Systems.” The Journal of Technology Transfer 31 (1): 101–113. doi:10.1007/s10961-005-5016-4.
   Google Scholar
• Hall, L., and S. Bagchi-Sen. 2001. “An Analysis of R&D, Innovation and Business Performance in the US Biotechnology Industry.” International Journal of Biotechnology 3 (3): 267–286. doi:10.1504/IJBT.2001.000165.
   Google Scholar
• Hall, L., and S. Bagchi-Sen. 2002. “A Study of R&D, Innovation, and Business Performance in the Canadian Biotechnology Industry.” Technovation 22 (4): 231–244. doi:10.1016/S0166-4972(01)00016-5.
   Web of Science ®Google Scholar
• Hudson, R. 2003. “Fuzzy Concepts and Sloppy Thinking: Reflections on Recent Developments in Critical Regional Studies.” Regional Studies 37: 741–746. doi:10.1080/0034340032000108822.
   Web of Science ®Google Scholar
• Huizingh, E. 2011. “Open Innovation: State of the art and Future Perspectives.” Technovation 31 (1): 2–9. doi:10.1016/j.technovation.2010.10.002.
   Web of Science ®Google Scholar
• Kaiser, R., and H. Prange. 2004. “The Reconfiguration of National Innovation Systems—the Example of German Biotechnology.” Research Policy 33 (3): 395–408. doi:10.1016/j.respol.2003.09.001.
   Web of Science ®Google Scholar
• Kang, K., and H. Park. 2012. “Influence of Government R&D Support and Inter-Firm Collaborations on Innovation in Korean Biotechnology SMEs.” Technovation 32 (1): 68–78. doi:10.1016/j.technovation.2011.08.004.
   Web of Science ®Google Scholar
• Kotsantonis, S., C. Pinney, and G. Serafeim. 2016. “ESG Integration in Investment Management: Myths and Realities.” Journal of Applied Corporate Finance 28 (2): 10–16. doi:10.1111/jacf.12169.
   Web of Science ®Google Scholar
• Kurata, H., T. Ishino, Y. Ohsima, and M. Yohda. 2022. “CDMOS Play a Critical Role in the Biopharmaceutical Ecosystem.” Frontiers in Bioengineering and Biotechnology 10: 841420. doi:10.3389/fbioe.2022.841420.
   PubMed Web of Science ®Google Scholar
• Lee, K., and F. Malerba. 2014. “Changes in Industry Leadership and Catch-up by The Latecomers: Toward a Theory of Catch-up Cycles. Future Perspective on Innovation and Governance in Development.” UNU-MERIT/MGSoG Conference, Maastricht, the Netherlands.
   Google Scholar
• Lee, K., and F. Malerba. 2017. “Catch-up Cycles and Changes in Industrial Leadership: Windows of Opportunity and Responses of Firms and Countries in the Evolution of Sectoral Systems.” Research Policy 46 (2): 338–351. doi:10.1016/j.respol.2016.09.006.
   Web of Science ®Google Scholar
• Lieberman, M., and D. Montgomery. 1988. “First-Mover Advantages.” Strategic Management Journal 9 (S1): 41–58. doi:10.1002/smj.4250090706.
   Web of Science ®Google Scholar
• Lozano, M. B., and J. Martínez-Ferrero. 2022. “Do Emerging and Developed Countries Differ in Terms of Sustainable Performance? Analysis of Board, Ownership and Country-level Factors.” Research in International Business and Finance 62: 101688. doi:10.1016/j.ribaf.2022.101688.2022.
   Web of Science ®Google Scholar
• Niosi, J. 2014. “Biotechnology: A Case of Delayed International Convergence?” International Journal of Biotechnology 13 (1-3): 5–21. doi:10.1504/IJBT.2014.059648.
   Google Scholar
• Peck, J. 2003. “Fuzzy Old World: A Response to Markusen.” Regional Studies 37: 729–740. doi:10.1080/0034340032000108813.
   Web of Science ®Google Scholar
• Pisano, G. 2006. Science Business: The Promise, the Reality, and the Future of Biotech. Boston, MA: Harvard Business School Press.
   Google Scholar
• Ramos, J. 2021. “Shifting the Mindset of Commercial Lawyers to Rewire Contracts, to Mitigate Climate Change More Effectively in Practice: The Chancery Lane Project.” Environmental Law Review 23 (1): 3–8. doi:10.1177/14614529211000152.
   Google Scholar
• Russo-Spena, T., and N. Di Paola. 2019. “Inbound Open Innovation in Biopharmaceutical Firms: Unpacking the Role of Absorptive Capacity.” Technology Analysis & Strategic Management 31 (1): 111–124. doi:10.1080/09537325.2018.1489047.
   Web of Science ®Google Scholar
• Schuhmacher, A., P. Germann, H. Trill, and O. Gassmann. 2013. “Models for Open Innovation in the Pharmaceutical Industry.” Drug Discovery Today 18 (23-24): 1133–1137. doi:10.1016/j.drudis.2013.07.013.
   PubMed Web of Science ®Google Scholar
• Serna-Gallegos, T., C. La-Fargue, and K. Tewari. 2018. “The Ecstacy of Gold: Patent Expirations for Trastuzumab, Bevacizumab, Rituximab, and Cetuximab.” Recent Patents on Biotechnology 12 (2): 101–112. doi:10.2174/1872208311666171122152131.
   PubMedGoogle Scholar
• Shin, K., E. Kim, and E. Jeong. 2018. “Structural Relationship and Influence Between Open Innovation Capacities and Performances.” Sustainability 10 (8): 2787. doi:10.3390/su10082787.
   Web of Science ®Google Scholar
• Stotz, O. 2021. “Expected and Realized Returns on Stocks with High-and Low-ESG Exposure.” Journal of Asset Management 22 (2): 133–150. doi:10.1057/s41260-020-00203-z.
   Web of Science ®Google Scholar
• Voss, C., N. Tsikriktsis, and M. Frohlich. 2002. “Case Research in Operations Management.” International Journal of Operations and Production Management 22: 195–219. doi:10.1108/01443570210414329.
   Web of Science ®Google Scholar
• Watkins, A., T. Papaioannou, J. Mugwagwa, and D. Kale. 2015. “National Innovation Systems and the Intermediary Role of Industry Associations in Building Institutional Capacities for Innovation in Developing Countries: A Critical Review of the Literature.” Research Policy 44 (8): 1407–1418. doi:10.1016/j.respol.2015.05.004.
   Web of Science ®Google Scholar
• Yeung, A., A. Atanasov, H. Sheridan, E. Klager, F. Eibensteiner, S. Völkl-Kernsock, H. Willschke, and E. Schaden. 2021. “Open Innovation in Medical and Pharmaceutical Research: A Literature Landscape Analysis.” Frontiers in Pharmacology 11: 587526. doi:10.3389/fphar.2020.587526.
   PubMed Web of Science ®Google Scholar
• Yin, R. 2017. Case Study Research and Applications: Design and Methods. Thousand Oaks, CA: SAGE Publications.
   Google Scholar
• Yu, D., L. Razon, and R. Tan. 2020. “Can Global Pharmaceutical Supply Chains Scale up Sustainably for the COVID-19 Crisis?” Resources, Conservation, and Recycling 159: 104868. doi:10.1016/j.resconrec.2020.104868.
   PubMed Web of Science ®Google Scholar
• Zhang, F., P. Cooke, and F. Wu. 2011. “State-sponsored Research and Development: A Case Study of China's Biotechnology.” Regional Studies 45 (5): 575–595. doi:10.1080/00343401003604663.
   Web of Science ®Google Scholar